Literature DB >> 25547850

Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium.

Matteo Muti1, Claudia Del Grande2, Laura Musetti2, Donatella Marazziti3, Milo Turri1, Marco Cirronis1, Irene Pergentini2, Martina Corsi2, Liliana Dell'Osso2, Giovanni Umberto Corsini1.   

Abstract

Recent findings support the role of purinergic system dysfunction in the pathophysiology of bipolar disorder (BD). The present study aimed to evaluate the pattern of serum uric acid levels in a sample of 98 BD I patients followed-up prospectively in a naturalistic study and treated with lithium monotherapy or in association with other mood stabilizers (valproate or carbamazepine), in relation to different phases of illness and to pharmacological treatment. The results showed that uric acid levels were significantly higher in patients suffering from a manic/mixed episode, than in those euthymic or during a depressive phase. Further, these levels were related to the Clinical Global Impression-Bipolar Version (CGI-BP) scale score for the severity of manic symptoms. A positive correlation was found also with male sex and with serum lithium levels. These findings suggest that a dysregulation of the purinergic system may occur during manic/mixed episodes, and they support a possible role of serum uric acid levels as a state-dependent marker of BD manic phases.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biological marker; Bipolar disorder; Lithium; Purinergic system; Uric acid

Mesh:

Substances:

Year:  2014        PMID: 25547850     DOI: 10.1016/j.psychres.2014.11.038

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

Review 3.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Fructose and Uric Acid as Drivers of a Hyperactive Foraging Response: A Clue to Behavioral Disorders Associated with Impulsivity or Mania?

Authors:  Richard J Johnson; William L Wilson; Sondra T Bland; Miguel A Lanaspa
Journal:  Evol Hum Behav       Date:  2020-10-01       Impact factor: 4.178

5.  Comparison of Serum Uric Acid in Major Depressive Disorder and Bipolar Disorder: a Retrospective Chart Review Study.

Authors:  Soomin Kim; Sang Jin Rhee; Yoojin Song; Yong Min Ahn
Journal:  J Korean Med Sci       Date:  2020-07-20       Impact factor: 2.153

6.  Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder.

Authors:  Jingxu Chen; Hongmei Chen; Junhui Feng; Ligang Zhang; Juyan Li; Ran Li; Shaoli Wang; Ian Wilson; Alison Jones; Yunlong Tan; Fude Yang; Xu-Feng Huang
Journal:  BMC Psychiatry       Date:  2018-12-18       Impact factor: 3.630

7.  Patients With Drug-Naive Bipolar Disorder in Remission After 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations.

Authors:  Jing-Xu Chen; Li-Gang Zhang; Ke-Zhi Liu; Hong-Mei Chen; Shuang-Jiang Zhou; Ning Wang; Yun-Long Tan; Shao-Li Wang; Alison Jones; Fu-De Yang; Xu-Feng Huang
Journal:  Front Psychiatry       Date:  2019-10-31       Impact factor: 4.157

Review 8.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

9.  Individuals with bipolar disorder have a higher level of uric acid than major depressive disorder: a case-control study.

Authors:  Zhe Lu; Yingtan Wang; Guanglei Xun
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.